Robert H. Smith School of Business
The Motley Fool

Market Foolery Featured Podcasts

  • MarketFoolery 10.29.2014
    Fool Australia analyst Matt Joass discusses the investing landscape in Australia, “ghost cities” in China, and how American brands are viewed Down Under.
  • MarketFoolery: 10.28.2014
    The price of oil is dropping.  We analyze the best opportunities in oil stocks right now, plus the latest results from Twitter and Buffalo Wild Wings.  
  • MarketFoolery: 10.27.2014
    CVS and Rite Aid disable Apple Pay as they work on their own mobile payment system.  We analyze the battle for your wallet and dip into the Fool Mailbag and discuss short-term investments, stocks for the next 20 years, and Halloween candy.
Capital Business
Posted at 11:13 AM ET, 07/16/2012

GlaxoSmithKline buys Human Genome Sciences for $3.6B


Human Genome Sciences' headquarters in Rockville. (Jeffrey MacMillan - Capital Business)
British drugmaker GlaxoSmithKline has agreed to pay $3.6 billion for Rockville-based Human Genome Sciences after a months-long acquisition dispute over the company’s true value.

Glaxo has extended multiple buyout offers since April to both the HGS board of directors and its shareholders that valued the company at $2.6 billion, or $13 per share, but the company repeatedly rejected them as too low.

This latest agreement will fetch $14.25 per share in cash for HGS, a transaction value worth about $3.6 billion on an equity basis, or approximately $3 billion net of cash and debt, the companies said.

The deal brings an end to what had become an increasingly heated battle for control of the company.

Glaxo had attempted to bypass the board and purchase stock directly from investors. HGS then thwarted that effort with a poison pill, but gained a lawsuit from some disgruntled shareholders in response.

The two firms are development and marketing partners on several drugs, including Benlysta, which was approved by the Food and Drug Administration last year to treat systemic lupus.

By  |  11:13 AM ET, 07/16/2012

 
Read what others are saying
     

    © 2011 The Washington Post Company